Budget Impact Analysis of Lebrikizumab for Treating Severe Atopic Dermatitis
Abstract Introduction Lebrikizumab is a novel monoclonal antibody that targets interleukin-13, a pivotal factor in atopic dermatitis (AD). Previous studies revealed a positive benefit–risk profile of lebrikizumab as treatment for patients with moderate-to-severe AD. In Italy, lebrikizumab has been a...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-07-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-025-01475-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849767154528813056 |
|---|---|
| author | Ippazio Cosimo Antonazzo Giampiero Girolomoni Cataldo Patruno Roberto Langella Veronica Ottobrino Lorenzo Giovanni Mantovani Paolo Angelo Cortesi |
| author_facet | Ippazio Cosimo Antonazzo Giampiero Girolomoni Cataldo Patruno Roberto Langella Veronica Ottobrino Lorenzo Giovanni Mantovani Paolo Angelo Cortesi |
| author_sort | Ippazio Cosimo Antonazzo |
| collection | DOAJ |
| description | Abstract Introduction Lebrikizumab is a novel monoclonal antibody that targets interleukin-13, a pivotal factor in atopic dermatitis (AD). Previous studies revealed a positive benefit–risk profile of lebrikizumab as treatment for patients with moderate-to-severe AD. In Italy, lebrikizumab has been approved and reimbursed as treatment for patients with severe AD (aged 12 years or older and with an Eczema Area and Severity Index (EASI) ≥ 24). However, data on economic impact of lebrikizumab in these subjects are still scarce. This study aimed to assess the budget impact of lebrikizumab in Italian patients with severe AD, according to Italian Medicine Agency (AIFA) reimbursement criteria, from the Italian National Healthcare System (NHS) perspective. Methods The budget impact analysis model was used to estimate the economic impact of lebrikizumab as treatment of patients with severe AD by comparing the total budget expenditure under two scenarios: scenario A, which includes the current standard of care with biologic agents (dupilumab and tralokinumab), and scenario B, which includes dupilumab and tralokinumab along with the introduction of lebrikizumab. The analysis was conducted by adopting the Italian NHS perspective and a 3-year time horizon. The clinical data input was based on published evidence, pivotal clinical trial, and expert opinion. Cost data was retrieved from the Italian tariff and literature. One-way sensitivity analysis was conducted to assess the robustness of the model. Results The base case analysis, conducted over a 3-year period, estimated that the number of patients treated with lebrikizumab increased from 1198 in the first year to 5849 in the final year of the simulation. The adoption of lebrikizumab for patient treatment resulted in a cumulative cost-saving of €3.3 million in 3 years (€786 thousand in the first year, − €1.7 million in the second year, and − €2.4 in the last year). The number of patients potentially eligible to the treatment, the injection site reaction cost, and the injection site reaction rate were the main drivers of the findings. Conclusion The availability of lebrikizumab as treatment for patients with severe AD would result in cost savings for Italy. Given the paucity of economic data on lebrikizumab, new economic studies should be conducted to confirm these findings. |
| format | Article |
| id | doaj-art-9595a95b0859491ca8e43fa55a7397cc |
| institution | DOAJ |
| issn | 2193-8210 2190-9172 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj-art-9595a95b0859491ca8e43fa55a7397cc2025-08-20T03:04:20ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722025-07-011592521253610.1007/s13555-025-01475-2Budget Impact Analysis of Lebrikizumab for Treating Severe Atopic DermatitisIppazio Cosimo Antonazzo0Giampiero Girolomoni1Cataldo Patruno2Roberto Langella3Veronica Ottobrino4Lorenzo Giovanni Mantovani5Paolo Angelo Cortesi6Research Centre on Public Health (CESP), University of Milano-BicoccaSection of Dermatology and Venereology, Department of Medicine, University of VeronaDepartment of Medicine and Health Sciences “Vincenzo Tiberio”, University of MoliseHeath Protection Agency of Milan (HPA-Milan)Almirall S.p.A.Research Centre on Public Health (CESP), University of Milano-BicoccaResearch Centre on Public Health (CESP), University of Milano-BicoccaAbstract Introduction Lebrikizumab is a novel monoclonal antibody that targets interleukin-13, a pivotal factor in atopic dermatitis (AD). Previous studies revealed a positive benefit–risk profile of lebrikizumab as treatment for patients with moderate-to-severe AD. In Italy, lebrikizumab has been approved and reimbursed as treatment for patients with severe AD (aged 12 years or older and with an Eczema Area and Severity Index (EASI) ≥ 24). However, data on economic impact of lebrikizumab in these subjects are still scarce. This study aimed to assess the budget impact of lebrikizumab in Italian patients with severe AD, according to Italian Medicine Agency (AIFA) reimbursement criteria, from the Italian National Healthcare System (NHS) perspective. Methods The budget impact analysis model was used to estimate the economic impact of lebrikizumab as treatment of patients with severe AD by comparing the total budget expenditure under two scenarios: scenario A, which includes the current standard of care with biologic agents (dupilumab and tralokinumab), and scenario B, which includes dupilumab and tralokinumab along with the introduction of lebrikizumab. The analysis was conducted by adopting the Italian NHS perspective and a 3-year time horizon. The clinical data input was based on published evidence, pivotal clinical trial, and expert opinion. Cost data was retrieved from the Italian tariff and literature. One-way sensitivity analysis was conducted to assess the robustness of the model. Results The base case analysis, conducted over a 3-year period, estimated that the number of patients treated with lebrikizumab increased from 1198 in the first year to 5849 in the final year of the simulation. The adoption of lebrikizumab for patient treatment resulted in a cumulative cost-saving of €3.3 million in 3 years (€786 thousand in the first year, − €1.7 million in the second year, and − €2.4 in the last year). The number of patients potentially eligible to the treatment, the injection site reaction cost, and the injection site reaction rate were the main drivers of the findings. Conclusion The availability of lebrikizumab as treatment for patients with severe AD would result in cost savings for Italy. Given the paucity of economic data on lebrikizumab, new economic studies should be conducted to confirm these findings.https://doi.org/10.1007/s13555-025-01475-2LebrikizumabBudget impact analysisSevere atopic dermatitisItalyPharmacoeconomics |
| spellingShingle | Ippazio Cosimo Antonazzo Giampiero Girolomoni Cataldo Patruno Roberto Langella Veronica Ottobrino Lorenzo Giovanni Mantovani Paolo Angelo Cortesi Budget Impact Analysis of Lebrikizumab for Treating Severe Atopic Dermatitis Dermatology and Therapy Lebrikizumab Budget impact analysis Severe atopic dermatitis Italy Pharmacoeconomics |
| title | Budget Impact Analysis of Lebrikizumab for Treating Severe Atopic Dermatitis |
| title_full | Budget Impact Analysis of Lebrikizumab for Treating Severe Atopic Dermatitis |
| title_fullStr | Budget Impact Analysis of Lebrikizumab for Treating Severe Atopic Dermatitis |
| title_full_unstemmed | Budget Impact Analysis of Lebrikizumab for Treating Severe Atopic Dermatitis |
| title_short | Budget Impact Analysis of Lebrikizumab for Treating Severe Atopic Dermatitis |
| title_sort | budget impact analysis of lebrikizumab for treating severe atopic dermatitis |
| topic | Lebrikizumab Budget impact analysis Severe atopic dermatitis Italy Pharmacoeconomics |
| url | https://doi.org/10.1007/s13555-025-01475-2 |
| work_keys_str_mv | AT ippaziocosimoantonazzo budgetimpactanalysisoflebrikizumabfortreatingsevereatopicdermatitis AT giampierogirolomoni budgetimpactanalysisoflebrikizumabfortreatingsevereatopicdermatitis AT cataldopatruno budgetimpactanalysisoflebrikizumabfortreatingsevereatopicdermatitis AT robertolangella budgetimpactanalysisoflebrikizumabfortreatingsevereatopicdermatitis AT veronicaottobrino budgetimpactanalysisoflebrikizumabfortreatingsevereatopicdermatitis AT lorenzogiovannimantovani budgetimpactanalysisoflebrikizumabfortreatingsevereatopicdermatitis AT paoloangelocortesi budgetimpactanalysisoflebrikizumabfortreatingsevereatopicdermatitis |